Jacqueline K. Shaia

Jacqueline K. Shaia

Auto-generated profile, based on publicly available information

Jacqueline K. Shaia

Case Western Reserve University School of Medicine, Cleveland, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2025 in American Journal of Ophthalmology
Verified
Journal Article
Open access
NANadia J. Abbass
Nadia J. Abbass
RNRaya Nahlawi
Raya Nahlawi
JSJacqueline K. Shaia
Jacqueline K. Shaia
KAKevin C. Allan
Kevin C. Allan
DKDavid . Kaelber
David . Kaelber
RSRishi P. Singh
Rishi P. Singh
The association between GLP-1 receptor agonists (GLP-1RA) and nonarteritic anterior ischemic optic neuropathy (NAION) remains unclear. Given the debilitating sequelae of NAION and rapid increase of GLP-1RA use, further research is essential to investigate this potential relationship. This study seeks to determine the risk of NAION and ischemic optic neuropathy (ION) in patients prescribed GLP-1RAs. Retrospective matched cohort study. TriNetX United States collaborative network. Patients ≥12 years old with type 2 diabetes (T2DM) and considered overweight or obese (high BMI), with at least one ophthalmology or neurology visit. Among T2DM patients, approximately 120,000 patients with a semaglutide prescription and 220,000 prescribed any GLP-1RA were compared to matched T2DM controls. Among high BMI patients, approximately 58,000 on semaglutide and 66,000 on any GLP-1RA were compared to matched controls. Patients prescribed semaglutide or any GLP-1RA were compared with those on non-GLP-1RA medications. Populations were propensity matched (1:1) on various demographic and risk factors to balance baseline cohorts. Cumulative incidence and risk of NAION and ION. Risk ratios (RR) with 95% confidence intervals (CI) were reported, with significance defined as CI 1.1. In T2DM patients prescribed semaglutide, the risk of NAION (RR = 0.7, 95% CI: 0.523-0.937) and ION (RR = 0.788, 95% CI: 0.609-1.102) after 5 years was not significantly increased compared to matched T2DM controls. Similarly, T2DM patients on any GLP-1RA demonstrated no significant difference in the risk of NAION (RR = 0.887, 95% CI: 0.735-1.071) or ION (RR = 0.969, 95% CI: 0.813-1.154) compared to controls. Furthermore, no increased risk of either outcome was found in the high BMI groups prescribed semaglutide or any GLP-1RA. The cumulative 5-year risk of NAION and ION in T2DM patients on semaglutide was 0.065% and 0.08%, respectively. In those with high BMI prescribed semaglutide, the risk of NAION and ION after 2 years was 0.038% and 0.404%, respectively. There was no significant increase in risk of NAION or ION in patients taking semaglutide or GLP-1RAs compared to T2DM or high BMI controls.

23 January 2025 in Ophthalmology
Verified
Journal Article
Open access
KAKevin C. Allan
Kevin C. Allan
JJJulia H. Joo
Julia H. Joo
SKSonia Kim
Sonia Kim
JSJacqueline Shaia
Jacqueline Shaia
DKDavid . Kaelber
David . Kaelber
ARAleksandra V. Rachitskaya
Aleksandra V. Rachitskaya
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been shown to exert neuroprotective and anti-inflammatory effects across multiple organ systems. This study investigated whether GLP-1RAs influence the risk for age-related ocular diseases. Retrospective cohort study. This study used an electronic health records platform of patients in the United States. Patients > 60 years with at least 5 years of ophthalmology follow-up and medication prescription documentation were included. There were 5 medication groups: GLP-1RA, metformin, insulin, statin, or aspirin users. Cohorts were propensity matched (1:1) on demographics and chronic disease risk factors. Outcomes of cataract, ocular hypertension, primary open-angle glaucoma, nonexudative age-related macular degeneration (AMD), and exudative AMD were compared 5 years after initial medication prescription. We then examined earlier time points within the 5-year period. Significance was defined as P < 0.05 with a hazard ratio (HR) threshold of > 1.1 or < 0.9. Of the 9669 patients taking GLP-1RAs, 84.4% had a diagnosis of diabetes with an average body mass index (BMI) of 36.2 kg/m2. Propensity-matched cohorts demonstrated that GLP-1RAs were associated with a reduced hazard of nonexudative AMD compared with metformin (HR, 0.68; 95% CI, 0.56-0.84), insulin (HR, 0.72; 95% CI, 0.58-0.89), and statins (HR, 0.70; 95% CI, 0.57-0.87). These findings were validated compared with aspirin and in an independent older cohort of patients. This significant reduction appeared after 3 years compared with metformin (HR, 0.69; 95% CI, 0.52-0.91), insulin (HR, 0.66; 95% CI, 0.5-0.87), and statins (HR, 0.67; 95% CI, 0.51-0.88). Time course results were validated using independent cohorts of propensity-matched patients taking medications for 3 years. Notably, GLP-1RAs also significantly reduced the risk of exudative AMD (HR, 0.70; 95% CI, 0.58-0.84) and primary open-angle glaucoma (HR, 0.58; 95% CI, 0.45-0.76) compared with insulin after 3 years. Use of GLP-1RAs showed no persistent impact on the risk of cataract formation or ocular hypertension compared with other medications. This study suggests that GLP-1RAs may reduce the risk of multiple age-related ocular diseases and the need for future prospective studies to validate these findings. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

13 February 2024 in Neurology
Verified
Journal Article
Closed access
JSJacqueline K. Shaia
Jacqueline K. Shaia
NSNeha Sharma
Neha Sharma
MKMadhukar Kumar
Madhukar Kumar
JCJeffrey Chu
Jeffrey Chu
CMChristopher Maatouk
Christopher Maatouk
DCDevon A. Cohen
Devon A. Cohen
With the obesity epidemic within the United States, the prevalence of idiopathic intracranial hypertension (IIH) is predicted to rise. IIH prevalence and racial disparities have rarely been reported in the United States. The purpose of this study was to evaluate the prevalence of IIH in a large national database while stratifying by sex, age, race, and ethnicity. This was a cross-sectional epidemiologic evaluation conducted in the TriNetX US Collaborative network using data from 2015 to 2022. Patients with an International Classification of Diseases code of IIH and papilledema or unspecified papilledema were included in the study. Any secondary cause of intracranial hypertension including cerebral neoplasms and hydrocephalus were excluded from the study. IIH trends were later compared with TriNetX cohort obesity trends. Prevalence and prevalence odds ratios (ORs) were calculated in Microsoft Excel and R Studio. Among 85 million patients in this database, a 1.35 times increase in the prevalence of IIH occurred between 2015 and 2022 from 7.3 (95% CI 6.9-7.7) individuals per 100,000 to 9.9 (95% CI 9.5-10.3) individuals per 100,000 in 2022. In 2022, Black female individuals had the highest prevalence of IIH with 22.7 individuals per 100,000 compared with the 13.7 White female individuals per 100,000. Patients aged 11-17 years showed the largest growth of IIH prevalence with female individuals increasing by 10 individuals per 100,000 by 2022. Overall, Black and Hispanic patients had the largest prevalence OR of IIH at 1.66 (95% CI 1.49-1.85) and 1.33 (95% CI 1.14-1.56), respectively, compared with White female patients. IIH is a rapidly increasing health care concern for the US population, particularly among adolescent patients. Black and Hispanic female individuals are most predominately affected by this incapacitating disorder.

23 February 2021 in Medical Science Educator
Verified
Journal Article
Closed access
PDF file
CECarrie A. Elzie
Carrie A. Elzie
JSJacqueline Shaia
Jacqueline Shaia

3 April 2022 in Gerontology & Geriatrics Education
Verified
Journal Article
Closed access
JBJason T. Bard
Jason T. Bard
HCHannah K. Chung
Hannah K. Chung
JSJacqueline K. Shaia
Jacqueline K. Shaia
LWLaurie L Wellman
Laurie L Wellman
CECarrie A. Elzie
Carrie A. Elzie
Given the growing prevalence of Alzheimer’s disease (AD), we assessed the impact of virtually embodying someone with progressive AD. This pilot explored students’ understanding of individuals’ needs with dementia, as well as, the efficacy of virtual reality (VR) as a curricular tool. Second-year medical students (n = 150) completed a pre-survey, Embodied Labs, Inc. Beatriz Lab VR module, and a post-survey. Most students knew someone with dementia (72%), were a family member of someone with dementia (52%) or had worked with a patient (61%) with dementia. Using paired survey questions, students reported significant increases in understanding how their lives would be affected by dementia (71% vs. 94%) and the needs of a person with dementia (64% vs. 95%) after VR. They reported increased understanding of being a caregiver of someone with dementia (24% vs. 81%) and the impact it can have on the entire family (64% vs. 97%). Overall students agreed this simulation made them think about their approach to clinical skills (94%) and should be utilized more in the curriculum (76%). This pilot study indicated that this VR experience can be used to advance understanding of a person’s experiences with dementia and that integrating VR into the medical curricula should be considered.

4 February 2024 in Ophthalmology Retina
Verified
Journal Article
Closed access
PSPriya Shukla
Priya Shukla
MRMatthew W. Russell
Matthew W. Russell
JMJustin C. Muste
Justin C. Muste
JSJacqueline K. Shaia
Jacqueline K. Shaia
MKMadhukar Kumar
Madhukar Kumar
KTKatherine E. Talcott
Katherine E. Talcott